Severe hemophilia A is a hereditary bleeding disorder characterized by a marked deficiency of factor VIII, a protein essential for normal blood coagulation. As described in Orphanet, the condition leads to frequent spontaneous hemorrhage and abnormal bleeding following minor injuries, surgical procedures, or dental extraction. According to available prevalence data, the condition occurs in approximately 1 to 9 per 100,000 individuals.

The defining feature of severe hemophilia A is recurrent, often spontaneous bleeding. Abnormal bleeding also follows minor trauma, surgery, and dental procedures. Bleeding episodes can vary in frequency and severity among individuals with this condition.

Severe hemophilia A arises from genetic variants that disrupt factor VIII production or function, resulting in severely reduced clotting capacity. The condition is hereditary. Specific inheritance pattern and gene information are not detailed in this packet’s data fields.

Diagnosis is established by laboratory measurement of factor VIII activity, which is severely reduced in affected individuals. Clinical history of spontaneous or excessive bleeding episodes is consistent with the diagnosis. Genetic evaluation may assist in further characterization of the underlying variant.

Management focuses on preventing and treating bleeding episodes through hemostatic strategies. Treatment plans are individualized and developed with hematology specialists in coagulation disorders. Active clinical research continues to expand the range of available therapeutic options.

With appropriate management, individuals with severe hemophilia A may experience reduced bleeding frequency and improved quality of life. For some individuals, development of inhibitory antibodies can complicate ongoing management. Long-term outcomes depend on therapeutic access and individual response to treatment.

Severe hemophilia A is a highly active area of clinical research. Numerous ongoing trials are investigating gene therapy approaches, novel hemostatic agents, and other therapeutic strategies. Current trial information is available through ClinicalTrials.gov.